Reaction Biology to Present Data at AACR 2023 Showcasing Expansive Capabilities in Immuno-Oncology Drug Discovery and Development

Malvern, PA – April 12, 2023 – Reaction Biology (“Reaction” or the “Company”), an industry-leading provider of drug discovery and development services, today announced that eleven abstracts highlighting data from the Company’s expanding suite of research offerings will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, 2023, in Orlando, Florida.

“The immuno-oncology landscape has undergone profound and encouraging progress in recent years and there is a growing demand for large molecule services in the search for new treatment options for patients with difficult-to-treat cancers,” said Haiching Ma, Ph.D., Chief Scientific Officer of Reaction Biology. “At AACR 2023, we look forward to showcasing data from our expansive suite of in vitro assays and in vivo tumor models that can provide our customers with solutions to help accelerate the identification and validation of important new drug candidates.”

New data will be presented on the Company’s innovative assay technologies, preclinical profiling models and proprietary screening platforms. The full range of data presented at AACR include:

• Humanized MOLM-13 AML model as a versatile tool to study immune-activating agents (Sunday, April 16, 2023, 1:30 – 5:00 PM; Poster Section 2, Poster Board Number: 1, Permanent Abstract Number: 33)
• Exploiting macrophage differentiation and plasticity as an immunomodulating strategy (Sunday, April 16, 2023, 1:30 – 5:00 PM; Poster Section 23, Poster Board Number: 11, Permanent Abstract Number: 671)
• Characterization of the selective inhibitory effect of KRas inhibitors in different cellular assay formats (Sunday, April 16, 2023, 1:30 – 5:00 PM; Poster Section 19, Poster Board Number: 16, Permanent Abstract Number: 549)
• Application of NanoBRET target engagement cellular assay for development of inhibitors against protein kinases, RAS, and epigenetic proteins in cancer therapy (Monday, April 17, 2023, 1:30 – 5:00 PM; Poster Section 17, Poster Board Number: 18, Permanent Abstract Number: 2764)
• Assay toolkit for the discovery of new RAS pathway inhibitors (Monday, April 17, 2023, 1:30 – 5:00 PM; Poster Section 11, Poster Board Number: 8, Permanent Abstract Number: 2624)
• Immunophenotyping of responses to immunotherapy in syngeneic tumor models using
  multiplex immunofluorescence compared to multiparametric flow cytometry (Tuesday, April 18, 2023, 9:00 AM – 12:30 PM; Poster Section 25, Poster Board Number: 10, Permanent Abstract Number: 4148)
• Use of luciferase-labeled target cells to explore immune cell killing in high throughput format in 2D and 3D co-cultures (Tuesday, April 18, 2023, 9:00 AM – 12:30 PM; Poster Section 40, Poster Board Number: 5, Permanent Abstract Number: 4419)
• Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics (Tuesday, April 18, 2023, 1:30 – 5:00 PM; Poster Section 25, Poster Board Number: 7, Permanent Abstract Number: 5194)
• Introduction of a platform for preclinical profiling of drug conjugates: a case study with
  sacituzumab govitecan (Tuesday, April 18, 2023, 1:30 – 5:00 PM; Poster Section 14, Poster Board Number: 6, Permanent Abstract Number: 4895)
• Cell-based assay to support development and characterization of new drugs in immuno-oncology (Wednesday, April 19, 2023, 9:00 AM – 12:30 PM; Poster Section 38, Poster Board Number: 22, Permanent Abstract Number: 6650)
• Identification of CDK15 activating cyclins by a recombinant co-expression approach (Wednesday, April 19, 2023, 9:00 AM – 12:30 PM; Poster Section 9, Poster Board Number: 9, Permanent Abstract Number: 5980)

“Over the past year, we have made significant investments in talent, infrastructure and resources to expand our preclinical oncology and immuno-oncology drug discovery and development services,” said John H. Johnson, Chief Executive Officer of Reaction Biology. “We maintain one of the broadest collections of syngeneic tumor models, and largest target panels and assays for kinase, KRAS and epigenetics, in addition to well-characterized tumor cell lines and highly qualified technicians using our state-of-the-art laboratories. Our efforts to deliver high integrity data with passionate customer service to help biopharmaceutical companies discover and develop innovative medicines more effectively underscores why we continue to be a preferred global partner of choice.”

Copies of the poster presentations will be available at Reaction Biology’s booth (#1527) during exhibit hall hours from April 14 – 19.

Founded in 2001, Reaction Biology is a global contract research organization (CRO) that provides drug discovery and development services to biopharmaceutical customers worldwide. Reaction specializes in supporting research goals with capabilities that include protein and peptide production, biochemical and biophysical assays, high throughput screening, exploratory toxicology, biomarker discovery tools, and an extensive array of cell-based and pharmacological assays modelling various diseases. Reaction also provides Good Manufacturing Practice (GMP) and Good Laboratory Practice (GLP) analytical and functional bioassays for testing potency, efficacy, and safety of large biological molecules, enabling clinical and commercial manufacturing batch release. Reaction has helped to advance many of its customers’ molecules through discovery and development pipeline stages into later clinical phases. These molecules may ultimately benefit patients living with cancer and other serious diseases. Reaction maintains one of the largest panels of kinase assays in the world with over 750 unique assays and performs more than 5,000 client projects annually with its over 2,000 validated assays.  

Reaction has laboratory facilities in Malvern, PA, Hershey, PA, Freiburg, Germany, and Heidelberg, Germany. For more information, visit www.ReactionBiology.com and follow us on Twitter @ReactionBiology and on LinkedIn.